Lymphoma Clinical Trials in Colorado

Showing 461-480 of 481 trials

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

NCT00510471

The treatment being investigated is a patient- and tumor-specific therapy known as a personalized active immunotherapy. Personalized active immunotherapy is an attempt to use a person's own immune system to combat disease. Sargramostim (a.k.a. GM-CSF) is given together with the personalized active immunotherapy because it may increase the immune system's response and, therefore, aid in the effect of the personalized active immunotherapy. This approach has previously been studied in patients with follicular Non-Hodgkin's lymphoma and other B-cell malignancies. Encouraging efficacy results and a favorable safety profile have been seen to date in these studies.

Non-Hodgkin's Lymphoma

Genitope CorporationStarted May 2007

Los Angeles, California, United States • Denver, Colorado, United States • Indianapolis, Indiana, United States +6 more locations

COMPLETEDPhase 250 miles

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT00063713

The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.

Mantle Cell Lymphoma

Millennium Pharmaceuticals, Inc.152 participantsStarted Jun 2003

Birmingham, Alabama, United States • Berkeley, California, United States • Duarte, California, United States +32 more locations

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma Trials in Other Cities

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Other Conditions in Colorado